Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report

Alectinib is a key drug for treating anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Alectinib-induced hepatotoxicity is less common than that through other ALK inhibitors, such as crizotinib or ceritinib. Herein, we describe a case of ALK-positive adenocarcinoma succes...

Descripción completa

Detalles Bibliográficos
Autores principales: Makimoto, Go, Kawakado, Keita, Nakanishi, Masamoto, Tamura, Tomoki, Kuyama, Shoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983536/
https://www.ncbi.nlm.nih.gov/pubmed/33776703
http://dx.doi.org/10.1159/000513624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983536/
https://www.ncbi.nlm.nih.gov/pubmed/33776703
http://dx.doi.org/10.1159/000513624

Ejemplares similares